HIV Diagnostics - Company Evaluation Report, 2025 (Abridged Report)

The HIV Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for HIV Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 100 companies, of which the Top 14 HIV DiagnosticsCompanies were categorized and recognized as the quadrant leaders.

Market growth can be attributed to the rising prevalence of HIV/AIDS, the advantages offered by point-of-care instruments & kits, and increasing initiatives for HIV awareness campaigns. However, the high cost of NATs, operational barriers, and the shortage of skilled laboratory technicians are key factors restraining the market growth. The high growth potential of emerging economies and the trend of self-testing are expected to provide lucrative opportunities for market players during the forecast period.

In this report, the HIV diagnostics market has been segmented based on product, test type, end user, and region.

The HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominated the global market in 2023. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North America.

However, the Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this region.

The 360 Quadrant maps the HIV Diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the HIV Diagnosticsquadrant. The top criteria for product footprint evaluation included BY test type (screening, confirmatory, monitoring, and other HIV diagnostic tests), by PRODUCT (instruments, and software & services) BY END USer (diagnostic laboratories, hospitals, blood banks, home care settings, and other end users.)

Key Players:

Key players in this market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland). These players adopt various strategies, such as product launches, expansions, acquisitions, and collaborations, to excel in this market.

Abbott (US):

Abbott is a leading player in the HIV diagnostics market, known for its impactful Company Product Portfolio that includes FDA- and CE-approved products. The company's strong Company Market Share in the U.S. is complemented by its strategic focus on expanding its presence in emerging markets through varied Company Positioning strategies. By leveraging inorganic growth strategies, such as collaborations and acquisitions, Abbott aims to bolster its Company Ranking.

Siemens Healthineers AG (Germany):

Siemens Healthineers is a cornerstone in the HIV diagnostics sphere, providing a broad array of medical solutions. Their focus on organic strategies and innovation has allowed them to maintain a competitive Company Positioning. With a significant presence in Europe, America, and emerging markets, they continue to excel in Company Market Share by offering innovative products that meet health sector demands.

Thermo Fisher Scientific (US):

With a comprehensive Company Product Portfolio that spans PCR-based assays and immunoassays, Thermo Fisher Scientific remains a leader. Their strategies focus on regulatory approvals and strategic acquisitions to enhance their Company Market Share. Through collaboration with healthcare organizations, they aim to boost early HIV detection and improve global health access, effectively securing their Company Positioning and Company Ranking in the market.


1 Introduction
1.1 Market Definition
1.2 Inclusions & Exclusions
1.3 Stakeholders
2 Executive Summary
3 Market Overview
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Rising Prevalence Of Hiv/Aids
3.2.1.2 Increasing Number Of Blood Transfusions & Blood Donations
3.2.1.3 Advantages Offered By Poc Diagnostic Kits & Instruments
3.2.1.4 Increasing Initiatives For Hiv Awareness Campaigns
3.2.2 Restraints
3.2.2.1 High Cost Of Nats
3.2.3 Opportunities
3.2.3.1 High Growth Potential Of Emerging Economies
3.2.3.2 Trend Of Self-testing And Growing Preference For At-home Diagnostic Kits
3.2.4 Challenges
3.2.4.1 Operational Barriers And Shortage Of Skilled Laboratory Technicians
3.3 Trends/Disruptions Impacting Customers’ Businesses
3.4 Value Chain Analysis
3.5 Supply Chain Analysis
3.6 Ecosystem Analysis
3.7 Technology Analysis
3.7.1 Key Technologies
3.7.1.1 Elisa
3.7.2 Complementary Technologies
3.7.2.1 Western Blot Tests
3.7.3 Adjacent Technologies
3.7.3.1 Pcr
3.8 Patent Analysis
3.9 Key Conferences & Events, 2025–2026
3.10 Porter’s Five Forces Analysis
3.10.1 Threat Of New Entrants
3.10.2 Threat Of Substitutes
3.10.3 Bargaining Power Of Buyers
3.10.4 Bargaining Power Of Suppliers
3.10.5 Intensity Of Competitive Rivalry
3.11 Impact Of Ai/Generative Ai On Hiv Diagnostics Market
3.11.1 Market Potential Of Ai In Hiv Diagnostics
3.11.2 Ai Use Cases
3.11.3 Company Implementation Of Ai
3.11.4 Future Of Ai/Generative Ai
4 Competitive Landscape
4.1 Overview
4.2 Key Player Strategies/Right To Win
4.2.1 Overview Of Strategies Adopted By Key Players In Hiv Diagnostics Market
4.3 Revenue Analysis, 2021–2023
4.4 Market Share Analysis, 2023
4.4.1 Ranking Of Key Market Players
4.5 Company Evaluation Matrix: Key Players, 2023
4.5.1 Stars
4.5.2 Emerging Leaders
4.5.3 Pervasive Players
4.5.4 Participants
4.5.5 Company Footprint: Key Players, 2023
4.5.5.1 Company Footprint
4.5.5.2 Region Footprint
4.5.5.3 Product Footprint
4.5.5.4 End-user Footprint
4.6 Company Evaluation Matrix: Startups/Smes, 2023
4.6.1 Progressive Companies
4.6.2 Responsive Companies
4.6.3 Dynamic Companies
4.6.4 Starting Blocks
4.6.5 Competitive Benchmarking: Startups/Smes, 2023
4.6.5.1 Detailed List Of Key Startups/Sme Players
4.6.5.2 Competitive Benchmarking Of Key Startups/Smes
4.7 Company Valuation & Financial Metrics
4.8 Brand/Product Comparison
4.9 Competitive Scenario
4.9.1 Product/Service Launches & Approvals
4.9.2 Product Launches & Approvals
4.9.3 Deals
4.9.4 Expansions
4.9.5 Other Developments
5 Company Profiles
5.1 Key Players
5.1.1 Abbott
5.1.1.1 Business Overview
5.1.1.2 Products/Services Offered
5.1.1.3 Recent Developments
5.1.1.3.1 Deals
5.1.1.4 Mnm View
5.1.1.4.1 Key Strengths
5.1.1.4.2 Strategic Choices
5.1.1.4.3 Weaknesses & Competitive Threats
5.1.2 Siemens Healthineers
5.1.2.1 Business Overview
5.1.2.2 Products/Services Offered
5.1.2.3 Recent Developments
5.1.2.3.1 Product/Service Launches & Approvals
5.1.2.3.2 Deals
5.1.2.3.3 Other Developments
5.1.2.4 Mnm View
5.1.2.4.1 Key Strengths
5.1.2.4.2 Strategic Choices
5.1.2.4.3 Weaknesses & Competitive Threats
5.1.3 Grifols, S.A.
5.1.3.1 Business Overview
5.1.3.2 Products/Services Offered
5.1.3.3 Recent Developments
5.1.3.3.1 Deals
5.1.3.4 Mnm View
5.1.3.4.1 Key Strengths
5.1.3.4.2 Strategic Choices
5.1.3.4.3 Weaknesses & Competitive Threats
5.1.4 Danaher Corporation
5.1.4.1 Business Overview
5.1.4.2 Products/Services Offered
5.1.4.3 Recent Developments
5.1.4.3.1 Product Launches & Approvals
5.1.4.3.2 Deals
5.1.4.3.3 Expansions
5.1.4.4 Mnm View
5.1.4.4.1 Key Strengths
5.1.4.4.2 Strategic Choices
5.1.4.4.3 Weaknesses & Competitive Threats
5.1.5 Thermo Fisher Scientific Inc.
5.1.5.1 Business Overview
5.1.5.2 Products/Services Offered
5.1.5.3 Recent Developments
5.1.5.3.1 Product/Service Launches & Approvals
5.1.5.3.2 Deals
5.1.5.4 Mnm View
5.1.5.4.1 Key Strengths
5.1.5.4.2 Strategic Choices
5.1.5.4.3 Weaknesses & Competitive Threats
5.1.6 Bio-rad Laboratories, Inc.
5.1.6.1 Business Overview
5.1.6.2 Products/Services Offered
5.1.6.2.1 Deals
5.1.7 F. Hoffmann-la Roche Ltd.
5.1.7.1 Business Overview
5.1.7.2 Products/Services Offered
5.1.7.3 Recent Developments
5.1.7.3.1 Product Launches & Approvals
5.1.7.3.2 Deals
5.1.7.3.3 Expansions
5.2 Other Players
5.2.1 Biomérieux
5.2.2 Hologic, Inc.
5.2.3 Qiagen
5.2.4 Bd
5.2.5 Trinity Biotech
5.2.6 Orasure Technologies, Inc.
5.2.7 Biosynex Sa
5.2.8 Wondfo
5.2.9 Getein Biotech, Inc.
5.2.10 Meril Life Sciences Pvt. Ltd.
5.2.11 Accubiotech Co., Ltd.
5.2.12 Biolytical Laboratories Inc.
5.2.13 Bio Lab Diagnostics (I) Private Limited
5.2.14 Alpine Biomedicals Pvt Ltd.
5.2.15 Molbio Diagnostics Pvt. Ltd.
5.2.16 Fortress Diagnostics
5.2.17 Advacare Pharma (Accuquik)
5.2.18 Adaltis S.R.L.
6 Appendix
6.1 Research Methodology
6.1.1 Research Data
6.1.1.1 Secondary Data
6.1.1.2 Primary Data
6.1.2 Study Assumptions
6.1.3 Research Limitations
6.1.4 Risk Assessment
6.2 Company Evaluation Matrix: Methodology
6.3 Author Details

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings